Published

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: BMJ Open
Date: 2026-07-01
Source: Crossref
DOI: 10.1136/bmjopen-2026-118471
PubMed: 42442821

Authors

Meyer Thomas D Vale Lauren N Ibrahim Maya Olmos Carolina Quevedo João Soares Jair C

Watch author

Derived topics and classifications

psilocybin Depression Clinical Trial Randomized Controlled Trial Review Article Treatment-Resistant Depression Healthcare Workers Safety Randomized Controlled Trial

Citation graph

40 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

10.1038/s41398-021-01500-w 10.1080/03007995.2019.1636017 10.1017/s2045796019000593 10.1016/s2215-0366(16)00082-1 10.1111/bdi.12609 10.1017/s0033291711002522 10.4088/jcp.16m11027 10.1017/s1352465819000080 10.1017/s0033291725000157 10.1177/0269881116636545 10.1186/s40345-022-00265-5 10.1016/j.cell.2020.03.020

Indexed papers citing this DOI

Acceptability and safety of two sequential doses of psilocybin in bipolar II depression: protocol for an open-label single-arm feasibility study2026-07-01

Related papers

Therapeutic Potential of Psychedelics in Treatment of Psychiatric Disorders, Part 2The Journal of Clinical Psychiatry · 2021-02-23 Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.Progress in neuro-psychopharmacology & biological psychiatry · 2018-02-02 G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?Ask the expert - Psychedelic substances · 2024-08-31 Med Check: Psilocybin for OCD, Nuplazid Vote, and MorePsychiatric News · 2022-08-01 The Return of Psychedelics: Still Time to Prevent TragedyPsychiatric News · 2021-03-31 Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-09-02 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01